Latest From David Wallace
Natco Claims Sole Exclusivity For Ibrutinib Tablets
Natco says it will be entitled to 180-day exclusivity for four strengths of ibrutinib tablets in the US after receiving tentative FDA approval.
Internal Alvogen Investigation Clears Chief Of Abuse Allegations
Alvogen has denied allegations levelled against founder Robert Wessman by a former employee who has claimed abusive behavior, despite an investigation instigated by the Alvogen board that cleared the company leader.
Canadian Biosimilars Body Calls For Expansion Of Switching
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
Nichi-Iko Resumes Production After Suspension
Nichi Iko says it has restarted production at its Namerikawa manufacturing plant after the Japanese firm was forced to suspend operations due to alleged GMP violations.
French Market Survives On New Generics
After a year that French industry association Gemme says has demonstrated the importance of a sustainable generics sector, the market continued to grow purely due to the contribution made by newly genericized molecules.
Zydus Claims Exclusivities After A Pair Of US Approvals
Zydus Cadila has claimed eligibility for periods of 180-day exclusivity linked to two of its recent US generic approvals, for rivals to Imbruvica and Opsumit.